Kymera Therapeutics, Inc. (KYMR) Stock Grade

About Kymera Therapeutics, Inc.'s fundamentals

Kymera Therapeutics is a biotechnology company with a market capitalization of $9.2 billion that is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -794.4%. The company's revenue declined 16.7% year-over-year, indicating contraction in its top-line performance. As a development-stage biotech firm, Kymera does not pay a dividend and lacks meaningful profitability metrics, which is typical for companies in early clinical or commercial stages focused on research and development investment.